Yuanxing Shen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuanxing Shen has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Chong Zhang
Department of Dermatology, Plastic Surgery Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
1 shared publication - Haoxiang Xu
Jiangsu Provincial Key Laboratory of Dermatology, Hospital for Skin Diseases, Institute of Dermatology Chinese Academy of Medical Sciences & Peking Union Medical College Nanjing China
1 shared publication - Qian Ye
Department of Dermatology, Plastic Surgery Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
1 shared publication - Shumeng Xue
Jiangsu Provincial Key Laboratory of Dermatology, Hospital for Skin Diseases, Institute of Dermatology Chinese Academy of Medical Sciences & Peking Union Medical College Nanjing China
1 shared publication - Yanyan He
Jiangsu Provincial Key Laboratory of Dermatology, Hospital for Skin Diseases, Institute of Dermatology Chinese Academy of Medical Sciences & Peking Union Medical College Nanjing China
1 shared publication Yi Zhang
Jiangsu Provincial Key Laboratory of Dermatology, Hospital for Skin Diseases, Institute of Dermatology Chinese Academy of Medical Sciences & Peking Union Medical College Nanjing China
1 shared publication
Latest Publications
- 8 September 2026
- Published by Wiley in Experimental Dermatology
- Vol. 35 (9) , e70350
Nicastrin Regulates Cutaneous Squamous Cell Carcinoma Progression Through the MAPK / ERK Signalling
Cutaneous squamous cell carcinoma (cSCC) is among the most common epithelial malignancies. Although cSCC arising in long‐standing acne inversa (AI) lesions is rare, it is a severe and clinically important complication of AI. Approximately one‐third of patients with AI harbour loss‐of‐function mutations in NCSTN . Whether NCSTN loss contributes to cSCC development remains unclear. To address this, we first examined its expression pattern in cSCC tissues. Interestingly, NCSTN expression was significantly decreased in cSCC tissues by immunohistochemistry (IHC) and Western blotting. Furthermore, loss of NCSTN promoted cSCC cell proliferation and migration in vitro and tumour growth in vivo. Proteomic analysis revealed that NCSTN deficiency promoted cell proliferation through activation of the MAPK/ERK signalling pathway, accompanied by reduced CLDN3 expression and alterations in cell‐adhesion‐related pathways. To validate the functional relevance of this signalling axis in vivo, we treated NCSTN‐knockdown tumour‐bearing mice with the ERK inhibitor SCH772984, which effectively suppressed tumour growth. Collectively, these findings demonstrate that loss of NCSTN drives cSCC progression through activation of MAPK/ERK signalling, and identify ERK signalling as a potential therapeutic vulnerability in NCSTN‐deficient cSCC.
- 8 September 2026
- Published by Wiley in Experimental Dermatology
- Vol. 35 (9) , e70350
Nicastrin Regulates Cutaneous Squamous Cell Carcinoma Progression Through the MAPK / ERK Signalling
Cutaneous squamous cell carcinoma (cSCC) is among the most common epithelial malignancies. Although cSCC arising in long‐standing acne inversa (AI) lesions is rare, it is a severe and clinically important complication of AI. Approximately one‐third of patients with AI harbour loss‐of‐function mutations in NCSTN . Whether NCSTN loss contributes to cSCC development remains unclear. To address this, we first examined its expression pattern in cSCC tissues. Interestingly, NCSTN expression was significantly decreased in cSCC tissues by immunohistochemistry (IHC) and Western blotting. Furthermore, loss of NCSTN promoted cSCC cell proliferation and migration in vitro and tumour growth in vivo. Proteomic analysis revealed that NCSTN deficiency promoted cell proliferation through activation of the MAPK/ERK signalling pathway, accompanied by reduced CLDN3 expression and alterations in cell‐adhesion‐related pathways. To validate the functional relevance of this signalling axis in vivo, we treated NCSTN‐knockdown tumour‐bearing mice with the ERK inhibitor SCH772984, which effectively suppressed tumour growth. Collectively, these findings demonstrate that loss of NCSTN drives cSCC progression through activation of MAPK/ERK signalling, and identify ERK signalling as a potential therapeutic vulnerability in NCSTN‐deficient cSCC.